NCM
RNAC icon

Nantahala Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Nantahala Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74,474
Closed -$1.54M – 140
2023
Q4 		$1.54M Buy
74,474
+1,141
+2% +$34.1K 0.09% 95
2023
Q3 		$2.33M Buy
73,333
+40,000
+120% +$1.34M 0.2% 86
2023
Q2 		$1.12M Hold
33,333
– – 0.11% 89
2023
Q1 		$1.39M Buy
+33,333
New +$1.57M 0.11% 88

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nantahala Capital Management's RNAC Position: Q1 2024 in Review

Nantahala Capital Management sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 74,474 shares — an estimated $1.54M sold.

Nantahala Capital Management first reported a position in RNAC in Q1 2023 and held it in 4 quarters. The position peaked at $2.33M in Q3 2023. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Nantahala Capital Management reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 74,474 Cartesian Therapeutics shares in Q1 2024, an estimated $1.54M.
  • Nantahala Capital Management first reported a position in Cartesian Therapeutics in Q1 2023 and held it in 4 quarters.
  • Nantahala Capital Management's Cartesian Therapeutics position peaked at $2.33M in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.